Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Arbaclofen follow-up shiftability study with open-label extension in autism spectrum disorder
2023-508407-20-00Phase 3Authorised
- Sponsor
- Fundación Investigación Biomédica Hospital General Universitario Gregorio Marañón
- Start
- Sep 2024
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 3, open-label, single-arm trial of arbaclofen in Autism Spectrum Disorder (ASD), sponsored by Fundación Investigación Biomédica Hospital General Universitario Gregorio Marañón. Primary endpoint: Change in power in the low frequency bands (theta/alpha). Planned start Sep 2024; status: authorised.
02
Drugs
arbaclofen
03
Conditions
Autism Spectrum Disorder (ASD)
Beyond the preview
Go deeper on 2023-508407-20-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-508407-20-00.